Cytokinetics Soars on Aficamten’s ‘Best-in-Class’ Performance in Phase III Cardio Study

Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.